The World Runs on Poor People’s Blood

And Nobody Wants to Talk About It

A long-form investigation into the international plasma market, the exploitation hiding in plain sight, and why the mainstream health conversation keeps looking the other way.

There’s a woman I’ll call Carolina. She works a twelve-hour overnight shift in a maquiladora in Matamoros, Mexico… one of those US-owned factories along the border where labour is cheap and the hours are brutal. After her shift ends, instead of going home to sleep, she joins a queue stretching toward the international bridge into Brownsville, Texas. She crosses. She walks to a clinic. She sits in a chair. She lets someone push a needle into her arm. And then she goes home.

She does this regularly. Not because she wants to. Because she has to.

Carolina’s story isn’t a metaphor. It’s operational reality for thousands of people living along the US-Mexico border. And it feeds one of the most lucrative, least scrutinised industries on the planet.

Let’s talk about blood plasma. Or more specifically, let’s talk about who’s actually providing it… and why the industry has worked so hard to make sure you think of it as charity.

“Donation.” That Word Is Doing Enormous Heavy Lifting.

First, a quick bit of biology, because it matters. Blood plasma is the yellowish liquid that makes up roughly 55 percent of your blood. Strip away the red cells, the white cells, the platelets, and what you’re left with is this protein-rich fluid that’s absolutely essential for manufacturing treatments for immune deficiencies, bleeding disorders, neurological conditions, and a long list of other serious diseases. Immunoglobulins. Albumin. Clotting factors. These aren’t optional medications. People’s lives depend on them.

Which is why the industry that collects and processes plasma is worth extraordinary amounts of money. The global plasma fractionation market was valued at over $40 billion in 2025, and analysts project it will nearly double to over $87 billion by the early 2030s. The industry calls its suppliers “donors.” The industry calls the transaction “donation.” These are curious choices of language for an arrangement that involves… payment. Cash. Money handed over in exchange for a biological fluid extracted from a human body.

You can call it whatever you like, but when someone needs the money and you need the plasma, that’s a market transaction. And markets, as we have discovered repeatedly throughout human history, tend to find the cheapest possible source of supply.

In this case, that source is poverty.

The Geography of Desperation

Here’s a detail that should make you pause. Researchers at the University of Michigan looked at where plasma collection centres in the United States are actually located. Their finding? These centres cluster most heavily in or near impoverished neighbourhoods. Not wealthy suburbs. Not middle-class commuter towns. Poor areas.

That isn’t a coincidence. That’s a business model.

Across the US, there are now over 1,247 plasma donation centres. More than there are community colleges. A significant number of them are concentrated along the Texas-Mexico border, in a region that contains some of the poorest counties in the entire state. In Brownsville, in Laredo, in El Paso… right on the doorstep of Mexico, where selling plasma is actually illegal.

Let me say that again. Selling plasma is illegal in Mexico. The Mexican government banned it in 1987 after paid plasma donation was linked to HIV outbreaks among both donors and the people receiving plasma-derived products. The ban exists because the medical and public health establishment recognised that when you pay vulnerable people to repeatedly sell their blood, things go wrong.

So what does the US industry do? It builds its centres as close to the Mexican border as geographically possible. It arranges shuttle buses to bring donors directly from the crossing points into Texas. It accepts payment from Mexican citizens crossing on tourist visas… or at least it did, until 2021, when US Customs and Border Protection rather abruptly declared that selling plasma counted as “labour for hire” and was therefore illegal under the visa category most border residents used.

Before that ruling, the border centres were processing roughly 2,300 units of plasma per week each… more than double the national average for non-border centres. You don’t get numbers like that from altruism. You get numbers like that from need.

The Numbers Behind the Needle

Let me give you a sense of what we’re actually talking about financially, because the asymmetry here is staggering.

On one side: a woman who crossed the border from Matamoros, where a week’s wages in a maquiladora might amount to roughly $50 to $70 US dollars. She receives around $30 for a unit of plasma, perhaps $40 or more. If she can donate twice a week, 104 times a year (which is the maximum the FDA permits in the US, by the way, a frequency the World Health Organisation and the American Red Cross both consider excessive), she might earn around $4,000 annually. That’s a meaningful supplement to an otherwise grinding income.

On the other side: companies like CSL Behring, which holds around 35 percent of the market in plasma fractionation revenue, and Grifols, the Spanish pharmaceutical giant, which reported over $6 billion in plasma-related sales in 2023 alone and recently announced revenues of over €7.5 billion for the year. Takeda Pharmaceutical pulls in around $4 to $5 billion from plasma-derived therapies. These are not small operations navigating thin margins. These are vast industrial enterprises extracting enormous profits from the proteins contained in human blood.

The ratio between what a donor receives and what that plasma eventually generates for shareholders sits somewhere between quietly obscene and loudly obscene, depending on your temperament.

One description that’s started circulating in industry and policy discussions refers to the United States as the “OPEC of Plasma.” And, honestly, that’s not inaccurate. Five countries… the US, Germany, Austria, the Czech Republic, and Hungary… provide around 80 percent of the world’s plasma supply. All five permit paid donations. Every other developed nation that bans payment? It imports its plasma products from those five. Europe still relies on the US for roughly 30 percent of its supply. Canada imports approximately 80 percent of its immune globulin from the US. The UK, until 2021, was almost entirely dependent on American paid-donor plasma.

The world has effectively outsourced its moral discomfort to a small number of countries willing to pay the poor for their blood, and then purchased the resulting medicines at premium prices. That’s not a supply chain. That’s a laundering operation for ethical compromise.

What Are We Actually Asking of People’s Bodies?

Here is something the industry talks about less than it should: we don’t fully know what donating plasma at maximum frequency does to the human body over time.

The FDA permits donors to give plasma twice a week, up to 104 times a year. The WHO advises against compensated plasma markets and has raised concerns about the consequences of excessively frequent donation. The American Red Cross recommends donating no more than 13 times a year, a frequency nearly eight times lower than what US regulations permit. The gap between those two positions should alarm you.

Research from the University of Colorado found that 29 percent of plasma sellers donate more than ten times over any given six-month period. Ten percent donate 40 or more times in that same window. These aren’t occasional contributors. For many people, this is a semi-regular obligation they’ve built their finances around.

Health researchers have documented associations between frequent plasma donation and decreased haemoglobin levels, iron deficiency, fatigue, and a temporarily weakened immune system. A longitudinal study in rural China, where paid plasma donation has a particularly grim history, found that commercial donors experienced significant declines in self-rated health, higher rates of hepatitis infection, and symptoms including weakness, nausea, and appetite loss.

Now, the industry will point out… and they’re not entirely wrong… that modern pathogen-safety measures have dramatically reduced transmission risks compared to earlier decades. That’s true. The products going into patients are, by all available evidence, safe. But the question of what happens to the donor over years of frequent extraction is a genuinely different question, and the honest answer is that we have surprisingly thin long-term data.

When you ask a health lawyer or a bioethicist about this gap in the evidence base, they don’t reassure you. They describe it as a significant problem. One analysis in a health law journal put it plainly: there is a gap in knowledge about the effects of frequent plasma donation, raising serious ethical questions. Without that knowledge, it’s impossible for an individual to give fully informed consent… and it’s impossible to establish what a fair price for that risk would even look like.

The industry’s trade group, the Plasma Protein Therapeutic Association, commissioned its own study and found no statistically significant differences between regular donors and non-donors. I’ll let you draw your own conclusions about the reliability of self-commissioned safety research.

Consent, Coercion, and the Comfortable Fiction of “Choice”

Let me be careful here, because this is where the debate gets philosophically messy, and I want to be honest about that rather than paper over it.

One argument in favour of paid plasma collection is straightforward: people have the right to decide what to do with their own bodies. If someone chooses to sell their plasma, who are we to tell them they can’t? That argument has real weight. Paternalistic prohibitions on bodily autonomy have a troubling history of their own.

But there’s a counter-argument that’s equally important, and it comes from a growing body of bioethical literature. Genuine autonomy requires genuine alternatives. When someone sells their plasma not because they’ve weighed up the options and made a free choice, but because the rent is due on Friday and there is no other option, the “choice” framing starts to collapse. As one academic analysis framed it, many donors come from circumstances of poverty that restrict their alternatives in a way that compromises their autonomy. That compromise represents what ethicists call an “undue inducement.”

A Canadian doctor described the location of plasma clinics in his city as “really targeting people who are low-income. They’re profiting off of poverty.” The industry would dispute that characterisation. The industry would say their centres welcome donors of all socioeconomic backgrounds. What the industry would not say is: show me the data on who actually walks through the door. Because we have that data, from multiple studies. The donors are overwhelmingly young, low-income, and financially precarious. That’s not a demographic coincidence.

One study found the arrangement so troubling it coined a term for it: a poverty tax. Not on income or purchases. A tax paid in blood, by the people who can least afford to pay anything at all.

The Geopolitical Sleight of Hand

Here’s the part of this story that gets almost no coverage, possibly because it implicates everyone rather conveniently.

Most developed nations have decided, officially, that paying people for plasma is ethically problematic. The WHO’s position is clear: voluntary, non-remunerated donation is preferable. The EU directive encourages voluntary donation. Multiple Canadian provinces have passed laws banning paid plasma collection. Britain avoided paid donation for decades.

And yet all of these countries are utterly dependent on plasma products manufactured from paid-donor plasma… primarily American paid-donor plasma. Canada imports 80 percent of its immune globulin from the US. European countries import 30 percent of their plasma supply. The UK spent twenty years buying almost exclusively American plasma.

What this amounts to is a moral outsourcing. These nations have crafted policies that prevent their own citizens from selling plasma… quite reasonably, on ethical grounds… while simultaneously relying on an industry that does exactly that, just out of sight. It’s the same logic that lets a country ban the manufacture of certain chemicals domestically while importing products that rely on those same chemicals being made somewhere else. The ethical concern evaporates as long as it’s happening over the border.

And nowhere is that border more literal, more visible, and more brutal than in Brownsville, Laredo, and El Paso.

What Happened in 2021, and Why It Matters

In June 2021, US Customs and Border Protection did something unexpected. They declared that selling plasma qualified as “labour for hire” and was therefore incompatible with the tourist visa status that most Mexican border residents used to cross into the US. Overnight, the pipeline of donors from Mexico was, officially, cut off.

The industry panicked. Grifols responded to hundreds of messages on its Spanish-language Facebook page. Centres saw their donor numbers drop sharply. The companies that operate border facilities… Grifols, CSL, and others… pushed back hard. Lawsuits followed. Lobbying intensified.

What the 2021 episode revealed, accidentally, was exactly how dependent the industry had become on this particular pipeline of economic desperation. When the border tightened during the early COVID-19 pandemic, donations dropped by 20 percent. Prices soared. Supply chains wobbled. The whole elegant architecture of the plasma economy trembled because a group of exhausted maquiladora workers couldn’t cross a bridge.

That kind of fragility doesn’t happen in industries that are sourcing from a robust and diversified supplier base. That fragility happens when you’ve built your business model around a single, very specific form of poverty. The industry’s analyst community now advises companies to invest in centres further from the border, somewhere they can “count on.” Read that however you like.

The Patients on the Other Side of This

I want to be clear about something, because this is important and the critique I’m making would be dishonest without it.

The medicines produced from plasma are not optional luxuries. People with primary immunodeficiencies need immunoglobulin infusions to survive. People with haemophilia need clotting factors. Patients with rare autoimmune conditions depend on plasma-derived therapies that have no synthetic alternative. These are real people, many of them also vulnerable, also struggling, whose lives are measurably better… or simply viable… because of these medications.

The existence of people who need these drugs doesn’t make the exploitation of people providing the raw material acceptable. But it does mean the question isn’t as simple as “stop the paid plasma industry.” The full-throated voluntarist approach hasn’t met demand anywhere it’s been tried. Countries that ban paid plasma don’t collect enough. The gap gets filled by imports from countries that haven’t banned it. The ethical calculus is genuinely complex.

What I’m arguing is not that the industry should be abolished tomorrow. I’m arguing that the conversation happening around it… in pharmaceutical boardrooms, in health policy papers, in the gentle both-sidesing of mainstream health journalism… is systematically understating what’s actually happening. It’s treating the financial desperation of donors as a neutral background condition rather than as the engine of the entire enterprise.

The Questions Nobody in the Mainstream Seems Willing to Ask

So let me ask them plainly.

If the pharmaceutical companies processing this plasma into billion-dollar products are operating ethically, why do their collection centres systematically cluster in the poorest postcodes? Why are shuttle buses arranged for people crossing international borders to sell blood in a country where their visa technically prohibits them from working? Why does the maximum allowable donation frequency in the US allow for twice the rate the Red Cross recommends? Why, given the scale of this industry’s revenues, has so little research been funded into the long-term health effects on donors? Why does the industry trade group commission its own health studies rather than agitating for independent longitudinal research?

And perhaps the most uncomfortable question of all: why is it that the wealthiest nations on Earth… nations with extraordinary medical infrastructure, top-flight pharmaceutical industries, and robust biomedical research budgets… have failed to develop synthetic alternatives to plasma-derived products that could remove the need to extract biological material from human beings at all? Some researchers are working on recombinant alternatives. Progress exists. But the urgency is… manageable, let’s say, for an industry that has a perfectly functioning supply of cheap plasma arriving twice a week.

A Final Word on Language

I want to come back to that word. “Donation.”

The plasma industry has been remarkably disciplined about language. Donors. Donation centres. Giving plasma. The word “donation” carries the moral weight of altruism. It implies a gift. It implies that what’s happening is an act of generosity freely given.

But when a woman in Matamoros who earns $60 a week crosses an international bridge before sunrise to sell her plasma so she can cover her household’s basic costs, that is not a gift. When a man in Flint, Michigan factors his twice-weekly plasma appointments into his budget like a part-time job because there is no other part-time job available to him, that is not a gift. When a young person in Brownsville donates the maximum 104 times a year… twice a week, every week, no holiday… because the rent doesn’t care about their haemoglobin levels, that is not a gift.

That is labour. It is poorly paid, physically extractive labour, performed by people with no meaningful alternative, on behalf of an industry generating tens of billions of dollars in annual revenue for its shareholders.

Calling it donation is a courtesy the industry has extended to itself. The rest of us aren’t obliged to go along with it.

The world runs on poor people’s blood. It has for decades. The companies involved are not small-time operators in grey markets. They are large, publicly listed pharmaceutical corporations with investor relations departments and ESG statements and glossy annual reports. The governments relying on their products are not failed states. They are advanced, wealthy democracies with international human rights commitments.

The story is in plain sight. It’s just that plain sight, in this case, requires looking at things that are uncomfortable for almost everyone involved.

Carolina is crossing the bridge again this morning. The queue stretches toward Texas. The clinic opens at seven.

Business as usual.

Sources consulted for this piece include reporting by Texas Monthly, ProPublica, Jacobin, NPR, Texas Public Radio, and academic literature from the NIH, University of Colorado Boulder, American Journal of Drug and Alcohol Abuse, Health Law & Policy Brief, and the journal Annals of Blood. Market data from Cornell University’s Emerging Markets Institute, Fortune Business Insights, and Mordor Intelligence.

Until Next Time